+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Urothelial Cancer Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4763899
  • Report
  • February 2019
  • Region: Global
  • 116 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • AstraZeneca PLC
  • Eisai Co. Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Novartis AG
  • MORE
Market Overview

The factors propelling the growth of the urothelial cancer drugs market are the emergence and popularity of targeted therapy and the rise in the incidence of urothelial cancer.

Urothelial cancer is the ninth most common malignancy in the world, with approximately 2.5 million patients and 420,000 newly diagnosed cases each year. Approximately 59% of bladder cancer cases occur in developed regions. The disease has the highest lifetime cost of care per patient among all tumors in the United States, due to its high relapse rate and invasive lifelong monitoring, including cystoscopy follow-ups.

As per the statistics released by the International Agency for Research on Cancer (IARC), 59% of all bladder cancer cases are observed in developed countries, with Belgium reporting the highest number of bladder cancer cases. Hence, the rise in the incidence of the disease has led to the growth of the urothelial cancer drugs market.

In addition, the urothelial cancer drugs market is likely to be benefitted from better therapies being approved by prominent drug regulatory organizations. Several novel treatments are predicted to see approvals, further supporting the growth of the market.

Scope of the Report

Urothelial carcinoma, also known as transitional cell carcinoma, is a cancerous tumor of the bladder, which also spreads to other parts of the body. The urothelium comprises the lining on the inside of the bladder, urethra, and ureters. It also consists of the renal pelvis. Urothelial carcinoma is the most widespread bladder cancer, as it accounts for over 90% of all bladder cancers.

Key Market Trends

Chemotherapy Under the Treatment Type is Expected to Witness the Fastest Growth During the Forecast Period

The chemotherapy segment is expected to dominate the market by treatment type, as the drugs may be used alone or in combination, depending on the purpose of its usage. Chemotherapy also finds application in treating invasive cancer and reducing the rate at which it spreads. Adjuvant chemotherapy and neoadjuvant chemotherapy are generating most of the revenue in the market, owing to an alarming rise in cases of bladder cancer and the rising uptake of chemotherapy to treat the same.

North America Dominates the Market and Expected to Follow the Same Trend Over the Forecast Period

The North American region has been dominating the urothelial cancer drugs market, due to factors, such as the presence of a large target population, increased adoption of novel therapeutics, and multiple product launches, along with a rising need to tackle bladder cancer. The market studied in the region is expected to grow during the forecast period.

Competitive Landscape

The urothelial cancer drugs market is expected to grow at a rapid pace in the next couple of years with intense competition among the players and a rising number of cases. Nimble players are already seen taking the collaboration route for the development of therapies and drugs, which would likely make the urothelial cancer drugs market crowded with new products in the next couple of years.
Note: Product cover images may vary from those shown
2 of 4


  • AstraZeneca PLC
  • Eisai Co. Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Novartis AG
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Emergence and Popularity of Targeted Therapy
4.2.2 Rise in Incidence of Urothelial Cancer
4.3 Market Restraints
4.3.1 Side Effects Associated with Drugs
4.3.2 Regulatory Issues
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 Urothelial Carcinoma
5.1.2 Squamous Cell Carcinoma
5.1.3 Adenocarcinoma
5.2 By Treatment
5.2.1 Chemotherapy
5.2.2 Immunotherapy
5.3 Geography
5.3.1 North America US Canada Mexico
5.3.2 Europe Germany UK France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Merck & Co. Inc.
6.1.2 F. Hoffmann-La Roche AG
6.1.3 Bristol-Myers Squibb Company
6.1.4 AstraZeneca PLC
6.1.5 Pfizer Inc.
6.1.6 Novartis AG
6.1.7 GlaxoSmithKline PLC
6.1.8 Sanofi SA
6.1.9 Eisai Co. Ltd

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Merck & Co. Inc.
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline PLC
  • Sanofi SA
  • Eisai Co. Ltd
Note: Product cover images may vary from those shown